Should hospitals face heightened legal liability for declining to adopt AI diagnostic tools that outperform physicians?

CHALLENGING ADVOCATE A'S WEAKEST CLAIM: FDA APPROVAL DOES NOT CONFER VALIDATED SUPERIORITY

Advocate A's legal argument pivots on the claim that 882 FDA-approved AI medical devices have 'regulatory standing' and that refusing to adopt them is therefore akin to ignoring proven superior equipment. This is the argument's most vulnerable joint, and the evidence directly undermines it.

A 2025 JAMA Network Open study of 903 FDA-approved AI-enabled medical devices found that clinical performance data was publicly available at the time of clearance for only 55.9% of devices. A separate review of 1,012 FDA approval summaries found an average AI Characteristics Transparency Reporting (ACTR) score of just 3.3 out of 17 — and 'nearly half of devices did not report a clinical study.' Critically, 96.4% of all FDA-cleared AI medical devices reached the market via the 510(k) pathway, which does not require prospective clinical trials and merely demands 'substantial equivalence' to a prior device. Furthermore, a scoping review found that only 3.6% of approved AI/ML devices reported the race or ethnicity of their validation cohorts, and fewer than 2% linked to peer-reviewed performance studies. The AHA has noted that 4.8% of AI devices were recalled within a median of 1.2 years of authorization — the most common cause being diagnostic or measurement errors.

This demolishes A's analogy to the mammography standards framework. MQSA was built on decades of population-level prospective evidence demonstrating real-world mortality reduction. By contrast, the FDA's 510(k) AI approval pathway is a speed-to-market mechanism, not a validation of clinical superiority. A hospital told it faces liability for not adopting an AI device that was cleared without a prospective trial, without demographic sub-group data, and with under-2% linkage to peer-reviewed evidence, would be facing liability for not adopting an under-validated tool. That is not a patient safety argument — it is a procurement mandate in liability's clothing.

SECOND CHALLENGE: BENCHMARK PERFORMANCE DOES NOT EQUAL REAL-WORLD CLINICAL PERFORMANCE

Advocate A cites the Harvard/Beth Israel Science study and the JAMA Network Open ChatGPT study as if benchmark accuracy translates directly into deployable clinical superiority. The empirical literature says otherwise. A peer-reviewed narrative review in MDPI Healthcare (2025) synthesizing studies from 2014–2024 found that 'AI's real-world effectiveness is frequently diminished when applied to diverse clinical settings, owing to methodological shortcomings, limited multicenter studies, and insufficient real-world validations.' Quantitatively, research published in Frontiers in Medicine found that 'real-world deployments often reveal performance drops of 15–30% due to population shifts and integration barriers.'

More directly relevant: a Mass General Brigham study published in JAMA Network Open testing 21 LLMs found that 'despite continued improvements, off-the-shelf large language models are not ready for unsupervised clinical-grade deployment.' The Mass General Brigham corresponding author stated plainly: 'Differential diagnoses are central to clinical reasoning and underlie the art of medicine that AI cannot currently replicate.' And a meta-analysis published in npj Digital Medicine found that in the aggregate, generative AI models were significantly inferior to expert physicians — with AI achieving a pooled accuracy of 52.1% versus expert physicians, with a 15.8 percentage point gap that was statistically significant (p=0.007). This is the current state of the systematic evidence, not cherry-picked studies featuring one model on one task.

MEANWHILE, NOTE THE SPECIFIC BENCHMARK AGAINST A: The DiagnosisArena benchmark across 28 medical specialties found that OpenAI's o1 model — the same model cited in A's Harvard study — achieved only 31.09% accuracy on complex, leakage-controlled clinical cases. o3-mini, the best performer, reached only 45.82%. These results highlight that AI benchmark performance varies dramatically depending on test design; controlled vignette-based studies with curated EHR data are systematically more favorable than clinically realistic, complex case benchmarks.

THIRD PILLAR: EQUITY AND THE ADOPTION DIVIDE ARGUE AGAINST LIABILITY-DRIVEN MANDATES

Advocate A frames non-adoption as institutional inertia that harms patients. But the empirical landscape of hospital AI adoption shows that who can adopt AI is deeply structured by resources, not indifference. According to a Nature Health nationwide study of 3,560 U.S. hospitals, 'hospital AI implementation is considerably clustered, with hotspots and coldspots of adoption,' and 'regions with greater healthcare access needs were less likely to have hospitals with AI-based predictive models.' A Medical Care study (2025) confirmed this: hospitals serving the most vulnerable areas (ADI Q4) were significantly less likely to apply ML predictive models (coef = −0.10, p = 0.01). Rural hospitals show 56% AI adoption versus 81% for urban hospitals; independent facilities show 37% versus 86% for multi-hospital systems.

Imposing liability for non-adoption in this environment does not neutrally accelerate adoption — it selectively punishes under-resourced hospitals serving the most vulnerable populations. The AHA itself flagged in its February 2026 response to HHS that 'resource and infrastructure barriers can exacerbate the digital divide in certain geographies, where rural and other underserved areas have less access to digital services.' Liability exposure without resource parity does not close the equity gap; it deepens it, potentially causing rural and independent hospitals to exit services they cannot safely AI-enable — the opposite of the patient safety outcome A claims to seek.

STEEL-MANNING ADVOCATE A: A's strongest response is that the above concerns — benchmark fragility, equity, and FDA validation gaps — are reasons to fix the ecosystem, not reasons to allow institutional non-adoption to persist unchallenged when specific tools ARE well-validated. This is a legitimate point in narrow cases. But it undermines the liability-as-mechanism argument rather than supporting it: if the preconditions for imposing liability (validated, generalizable, accessible AI tools) are not currently met for the vast majority of FDA-approved AI devices, then liability exposure for non-adoption would be triggered prematurely, producing perverse incentives toward adoption of under-validated tools for fear of legal risk. The proper mechanism is regulatory mandate tied to validated tools with equity-adjusted implementation support — not tort liability that operates without those guardrails.

WHERE ADVOCATE A CONCEDES GROUND AND WHAT IT REVEALS

Advocate A's Round 2 rebuttal contains a pivotal, underappreciated concession: they explicitly acknowledge that the equity objection is 'legitimate and serious' and propose incorporating it as a 'design constraint' on the liability standard. On its surface, this sounds like a nimble accommodation. In reality, it is a structural concession that exposes a fundamental flaw at the core of their argument.

Here is what the concession implies: Advocate A has effectively admitted that a blanket non-adoption liability standard cannot work. Their revised position now requires a 'tiered framework' — distinguishing well-resourced from under-resourced hospitals, and validated AI from under-validated AI, before liability attaches. But this is not the argument A made in Round 1. In Round 1, A argued that the legal mechanism 'already exists' and that hospitals face liability today for ignoring demonstrably superior AI. The revised position is fundamentally different: liability requires preconditions that A concedes do not uniformly exist. A has moved from 'the law should already be treating non-adoption as negligent' to 'we need a purpose-built tiered framework with safe harbors.' That is not a rebuttal of my position — it is a partial adoption of it.

CRITICAL PROBLEM ONE: THE TIERED FRAMEWORK A PROPOSES DOES NOT EXIST IN CURRENT TORT LAW — AND ITS ABSENCE IS PRECISELY THE DANGER

Advocate A cites the ALI Restatement (Third) of Torts: Medical Malpractice as evidence that the law is shifting toward an evidence-based reasonableness standard. This is a real development — the ALI did vote to approve this restatement in May 2024. However, A's framing overstates what this document achieves for their argument. Critical analysis reveals three important limitations:

First, ALI restatements are explicitly not legally binding. As the American Journal of Law and Medicine and the otolaryngology practice journal both note, 'while ALI restatements are not legally binding, they are frequently cited by state courts in judicial decisions.' Citation is not adoption. States must individually integrate these principles through litigation or legislation, a process that plays out over years or decades. The restatement does not create a current, operational liability standard for non-adoption of AI in any U.S. jurisdiction.

Second, the restatement's new standard — 'the care, skill, and knowledge regarded as competent among similar medical providers in the same or similar circumstances' — still anchors itself in what is 'competent among similar providers.' This is a relative standard that moves with professional practice, not an absolute standard that mandates adoption of any specific superior technology. The Conexiant summary of the JAMA special communication confirms the restatement 'maintains that those who have less than median or average skill may still be competent and qualified' — a formulation that provides no clear mechanism for imposing liability on an institution for non-adoption of a tool that its peers also haven't adopted.

Third, and most damaging to A's 'tiered framework' proposal: no court has yet applied non-adoption liability to AI tools in any jurisdiction. The University of Michigan / NCBI legal reference on AI liability in medicine notes directly that hospital direct liability theories for AI decisions are 'applicable to decisions the hospital makes as to AI, though thus far we have not seen any reported decisions on such fact patterns.' The Milbank Quarterly's peer-reviewed analysis confirms the dilemma explicitly: 'Health systems might be held liable for adopting AI/ML systems that they do not have the expertise to fully vet, but they could also be liable for failing to adopt AI/ML systems that improve care.' This symmetrical liability exposure — damned if you do, damned if you don't — is precisely the distortionary incentive structure my position warned against. A's proposed solution (a tiered framework with validation thresholds and safe harbors) is a regulatory design problem, not a feature of existing tort doctrine.

CRITICAL PROBLEM TWO: THE MASAI TRIAL ACTUALLY UNDERMINES, RATHER THAN SUPPORTS, A'S LIABILITY ARGUMENT

Advocate A presents the MASAI RCT as proof that real-world AI superiority in mammography is established and liability for non-adoption is therefore appropriate. This is a misuse of the evidence. The MASAI authors themselves — and multiple independent reviews — document serious generalizability limitations. The trial was conducted in a single Swedish national screening program, using one AI system (Transpara by ScreenPoint Medical), at four screening sites, with radiologists who were 'moderately to highly experienced.' The lead author, Kristina Lång, explicitly cautioned that implementation must be conducted 'cautiously, using tested AI tools and with continuous monitoring in place to ensure we have good data.'

Furthermore, a key observation from the Clinical Trial Vanguard's recent analysis is decisive: the MASAI evidence has 'outrun the authorization.' The FDA has not updated its clearance for AI mammography tools to reflect the system-level performance claims the MASAI trial would support. Lunit and iCAD — whose tools hold FDA clearance — have current U.S. labels that 'do not reflect the kind of system-level performance claim that MASAI's randomized data would support.' This creates an extraordinary paradox for A's argument: the best available real-world validation evidence exists for a Swedish AI system running within a Swedish screening program, but U.S. hospitals cannot lawfully deploy that specific system under a U.S. label that reflects MASAI-level superiority claims. A court applying non-adoption liability to a U.S. hospital would be holding the hospital liable for not deploying a capability that the FDA has not formally authorized any cleared device to claim.

The PRAIM Germany study cited by A (463,094 women, 12 sites) is the strongest multisite real-world evidence, but it was explicitly an 'observational, multicenter, real-world, noninferiority, implementation study' where 'radiologists voluntarily chose whether to use the AI system.' This voluntary adoption model is precisely what A opposes — and the positive results it produced show that appropriate incentives and professional uptake, not liability coercion, can drive AI integration in well-resourced systems with established radiologist workflows.

CRITICAL PROBLEM THREE: THE 'DOUBLE BIND' PROBLEM A IGNORES

A's tiered framework creates a double bind that the Hopkins Carey School of Business legal analysis captures precisely: physicians and hospitals 'are expected to rely on tools they may not fully understand, and are blamed whether they do or don't follow algorithmic advice.' The Milbank Quarterly's peer-reviewed analysis confirms: 'Because software is traditionally shielded from products liability, developers might introduce AI/ML systems too quickly into clinical care, offloading liability onto physicians and health care systems.' This is not a speculative harm. If hospitals face liability for non-adoption, AI developers have an incentive to market aggressively and early — knowing that liability for any resulting harms will fall to the clinical institution, not the developer. The 510(k) pathway I identified in Round 1 as clearing 96.4% of AI devices without prospective trials is the mechanism by which this offloading occurs. Non-adoption liability, without developer accountability reform, produces a perverse equilibrium in which hospitals are penalized for caution while developers bear no cost for premature marketing.

THE MAMMOGRAPHY EXCEPTION PROVES THE RULE — AND ACTUALLY SUPPORTS MY POSITION

I acknowledge, as I did in Round 1, that mammography AI presents the strongest case for validated superiority with prospective trial evidence. The MASAI and PRAIM data are genuinely compelling. But note what would be required to translate this into a legitimate non-adoption liability standard even in this best-case domain: (1) prospective RCT or large multisite evidence; (2) FDA regulatory updates to authorize the specific system-level performance claims the evidence supports; (3) reimbursement frameworks from CMS and private payers (which, as the MASAI analysis notes, are 'still being worked out'); and (4) implementation guidance that accounts for radiologist training and workflow integration. None of these preconditions are currently complete in the U.S. context — even for the domain where real-world evidence is strongest. This confirms rather than refutes my core claim: the proper pathway is regulatory mandate tied to validated tools and implementation support, not tort liability that operates without those guardrails.

In sum: A conceded that equity constraints are legitimate, then proposed a tiered solution that has no basis in existing law, applies only after conditions that aren't currently met, and ignores the symmetrical liability exposure that makes the tort mechanism an unreliable driver of safe adoption. The mammography evidence A marshals — while genuinely impressive — illustrates precisely why a tool-specific, regulation-first approach, not a generalized non-adoption tort liability standard, is the appropriate response to AI's demonstrated diagnostic potential.

ROUND 3 — STEEL-MAN, FINAL REBUTTAL, AND CRUX EVIDENCE

STEEL-MANNING ADVOCATE A

The strongest version of Advocate A's position is this: when AI tools are genuinely, prospectively validated at population scale — as AI-assisted mammography has been in the MASAI RCT (n=105,000+) and the PRAIM real-world implementation study (n=463,094) — the asymmetric incentive structure in current tort law creates a perverse equilibrium that protects institutional inertia at patient expense. Hospitals that can afford to adopt these validated tools but decline to do so face no legal accountability when a patient dies from a missed cancer that AI would have caught, while a hospital that adopts AI and uses it imperfectly faces potential liability for the adoption decision itself. The ALI Restatement's shift toward an evidence-based reasonableness standard, the evolving scholarly consensus, and the Singapore precedent all point in the same legal direction: once a tool is demonstrably accurate, affordable, and superior, deliberate institutional non-adoption in a well-resourced setting is increasingly difficult to distinguish from negligence. A's case is at its most compelling in this narrow, best-evidence domain — and it is not an entirely implausible view of where the law is headed.

WHY MY POSITION IS STILL STRONGER

A's steel-man, at its best, is a targeted argument about a narrow domain (well-validated AI tools with RCT-level evidence, deployed in well-resourced institutions) that has been progressively refined over three rounds to acknowledge equity concerns, validation gaps, and the absence of current legal precedent. That refinement process is itself the evidence that my position is correct: A began Round 1 by claiming the liability mechanism 'already exists,' ended Round 3 proposing a tiered framework with safe harbors, validation thresholds, and regulatory preconditions — none of which exist in current U.S. tort law. The destination A is pointing to is a regulatory design achievement, not a feature of existing doctrine, and the pathway A proposes — tort liability as the mechanism to get there — imports serious, documented harms that A has not resolved.

FIRST: THE DESKILLING AND AUTOMATION BIAS RISK IS NOW EMPIRICALLY DOCUMENTED, NOT SPECULATIVE

The clinical decision-making distortion I warned against in Round 1 has now been documented with quantitative evidence. A 2025-2026 scoping review in ScienceDirect (published March 2026, synthesizing empirical studies and RCTs through August 2025) found concrete, measurable deskilling effects from AI adoption: in a multicenter RCT in colonoscopy, adenoma detection rates dropped significantly from 28.4% to 22.4% when endoscopists reverted to non-AI procedures after repeated AI use. In radiology, a controlled study of 27 breast imaging radiologists found that erroneous AI prompts increased false-positive recalls by up to 12% even among experienced readers. In computational pathology, over 30% of participants reversed correct initial diagnoses when exposed to incorrect AI suggestions under time pressure. ECRI — the Emergency Care Research Institute — designated 'Navigating the AI diagnostic dilemma' as healthcare's number one patient safety concern for 2026, noting that AI 'can contribute to diagnostic mistakes for which radiologists can be held liable' and that these tools 'can perpetuate biases, come with a lack of transparency and erode clinicians' critical thinking skills.' A Wolters Kluwer survey (December 2025, n=518 providers and administrators) found that deskilling was the top concern among clinicians with less than five years of experience, with 33% ranking it in their top two concerns. This is not a hypothetical future risk — it is a documented, current phenomenon. Liability-driven adoption mandates would accelerate AI uptake without the training infrastructure, governance frameworks, and workflow design needed to prevent these specific, measurable harms.

SECOND: THE 'DOUBLE BIND' IDENTIFIED IN ROUND 2 IS CONFIRMED BY CURRENT LEGAL ANALYSIS

A WHO Europe survey released November 2025 found that legal uncertainty is the leading barrier to AI adoption across the region, and that fewer than one in ten countries have liability standards clarifying responsibility when an AI system makes an error — only four countries reported having such standards (Becker's Hospital Review, January 2026). The U.S. faces the same exposure. A's proposed solution — imposing non-adoption liability — resolves only one horn of this double bind without addressing the other: hospitals would still face liability for adopting AI they lack the expertise to vet, while developers remain shielded via the 510(k) pathway from the product liability that would otherwise discipline premature marketing. The NCBI Bookshelf analysis cited in my earlier rounds confirms this: 'evaluating biases in AI algorithmic models would then be impractical for most practitioners except those in large resource-rich healthcare institutions, thus exacerbating equity issues and hindering the adoption of advanced clinical algorithms in resource-constrained facilities, who must decide between facing higher liability or forgoing [AI].' A has not resolved this structural asymmetry — they have merely added a third horn to the dilemma.

THIRD: THE SINGAPORE PRECEDENT A CITES ACTUALLY REQUIRES MORE, NOT LESS, THAN A'S FRAMEWORK PROVIDES

Advocate A presents the Chan (2025) SAGE analysis as validating non-use liability as 'an extension of existing doctrine.' But the same analysis establishes that non-use negligence attaches only when AI has been 'found to be accurate, affordable, and superior in performance and efficacy to human doctors' — a conjunctive standard that requires all three elements. A 2025 University of Minnesota study found that approximately 65% of U.S. hospitals had adopted AI-assisted predictive tools, but only two-thirds of those institutions assessed the accuracy of these systems, and even fewer examined potential bias. If hospitals that already adopted AI cannot demonstrate they assessed accuracy or bias, the premise that hospitals declining to adopt can be held liable for not adopting similarly unvetted tools is self-defeating. Non-use liability without validated affordability, accuracy, and superiority determinations is not an extension of negligence doctrine — it is a departure from it.

FOURTH: THE PROPER MECHANISM IS ALREADY BEING CONSTRUCTED — WITHOUT TORT LIABILITY AS THE VANGUARD

The regulatory and governance architecture A calls for as a precondition is actively being built through channels that do not require liability coercion. The FDA's August 2025 final guidance on Predetermined Change Control Plans now formalizes continuous algorithm monitoring. The Joint Commission-CHAI guidance establishes governance standards for institutional AI deployment. ECRI's 2026 patient safety framework explicitly calls for 'a balanced approach to adoption, thoughtfully considering both the benefits and risks of AI to the diagnostic process.' The European Commission's AI Act establishes risk-based obligations for healthcare AI — building the validation infrastructure before liability attaches, not after. Akin Gump's 2025 regulatory analysis confirms that 'courts have not yet definitively resolved AI liability issues' and that standard of care 'may evolve to incorporate AI use where tools are widely adopted' — a formulation that treats adoption-level as the threshold, not a liability mandate as the mechanism to reach it. This is the responsible sequencing: regulatory validation infrastructure first, standard-of-care evolution as adoption normalizes, liability as the backstop once the system has integrity — not liability as the accelerant that forces adoption before the system has integrity.

CONCLUSION

Advocate A and I agree on the destination but disagree fundamentally on mechanism and sequencing. A's position, refined over three rounds, now amounts to: 'in a narrow domain with RCT-level evidence, well-resourced institutions should eventually face liability for non-adoption, once a tiered framework with safe harbors and validation thresholds is constructed.' That is not a meaningful distance from my position. Where we genuinely diverge is on whether imposing liability now — without the governance infrastructure, developer accountability reform, deskilling prevention frameworks, and equity resource supports in place — serves patients or harms them. The empirically documented deskilling effects, the WHO Europe finding that legal uncertainty is itself the leading barrier to adoption, the symmetrical double-bind liability exposure that non-adoption liability worsens, and the active construction of the regulatory infrastructure A demands as a precondition all point to the same conclusion: the responsible pathway is regulatory mandate tied to validated tools and implementation support — and liability as a backstop, not a vanguard.